OncoMatch/Clinical Trials/NCT04072042
BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma
Is NCT04072042 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Apatinib monotherapy for sarcoma.
Treatment: Apatinib monotherapy — The aim of this study is to evaluate the efficacy and safety of Apatinib monotherapy for relapsed or refractory advanced bone and soft tissue sarcoma with VEGFR-2 (KDR) 604A\>G polymorphism as predictive biomarker
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Disease stage
Metastatic disease required
advanced stage that complete surgical resection of all lesions are infeasible
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: standard NCCN guideline recommended first-line chemotherapy
refractory to prior treatment consisted of standard National Comprehensive Cancer Network (NCCN) guideline recommended first-line chemotherapy
Cannot have received: VEGFR tyrosine kinase inhibitor
Exception: previously treated with TKIs for less than 8 weeks but off treatment due to manageable complications such as wound complications or pneumothorax without adequate interventions. The complications is resolved and disappeared at enrollment.
previously treated with VEGFR TKIs for more than 8 weeks; previous treated with VEGFR TKIs but off treatment due to oncological assessment or dose-limiting complications given adequate interventions.
Lab requirements
Blood counts
adequate hemopoietic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
adequate renal, hepatic, and hemopoietic function; normal or controlled blood pressure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04072042 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior VEGFR tyrosine kinase inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 8 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages